In Medicare Population, Oncotype DX Linked to Less Chemo in High-Risk Patients, More in Low-Risk | GenomeWeb

NEW YORK (GenomeWeb) – New research by a team from Duke University on a nationally representative sample of Medicare patients has found that Genomic Health's Oncotype DX breast cancer test impacted the use of chemotherapy in tested women compared to untested women with early-stage breast cancer in some expected ways, though it was not associated with less chemo use in this cohort overall.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.